Skip to main content
BIOVENTIX PLC logo

BIOVENTIX PLC — Investor Relations & Filings

Ticker · BVXP ISIN · GB00B4QVDF07 LEI · 213800225MHX7LZQY108 IL Manufacturing
Open in API
Filings indexed 211 across all filing types
Latest filing 2021-10-18 Director's Dealing
Country GB United Kingdom
Listing IL BVXP

About BIOVENTIX PLC

https://www.bioventix.com/

Bioventix PLC is a biotechnology company that specializes in the development, creation, and commercial supply of high-affinity sheep monoclonal antibodies (SMAs). These antibodies are utilized by global diagnostic companies as critical components in clinical diagnostic platforms, particularly for blood testing immunoassays. The company's portfolio supports a variety of applications, including diagnostics for cardiovascular conditions (troponin), oncology, and neurodegenerative diseases such as Alzheimer's. In addition to its core antibody products, Bioventix also provides ELISA kits for monitoring exposure to industrial pollutants and offers contract services for the development of new SMAs for healthcare organizations.

Recent filings

Filing Released Lang Actions
Bioventix Plc - Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document explicitly announces a 'Director Dealing' involving the Chief Financial Officer, Bruce Hiscock, purchasing ordinary shares of the company. It provides details of the transaction, including the price, volume, and date, and is framed under the EU Market Abuse Regulation (MAR). This content directly corresponds to the definition of 'Director's Dealing' (insider trades by executives). Therefore, the appropriate filing code is DIRS.
2021-10-18 English
Bioventix Plc - Results for the year ended 30 June 2021
Audit Report / Information Classification · 98% confidence The document explicitly states it announces the 'audited results for the year ended 30 June 2021' and provides detailed financial highlights (Revenue, Profit before tax, Cash at year end) and a comprehensive review of the financial year 2020/2021. This content structure, covering a full fiscal year's performance, dividends, and future outlook based on audited figures, strongly indicates an Annual Report or a document closely associated with it. Since the text is a summary announcement containing key figures and dividend declarations, it is most likely the official Earnings Release (ER) or the primary document summarizing the Annual Report. Given the depth of financial detail and the mention of 'audited results', it is more substantial than a typical ER, but it is presented as an announcement released on October 15th, summarizing the year ended June 30th. In many regulatory contexts, the primary document summarizing the full year's audited results is often classified as the Annual Report (10-K equivalent for non-US filers) or the Earnings Release (ER) if it precedes the full filing. However, the presence of detailed financial performance review, dividend announcements (including special dividends), and the explicit mention of 'audited results' points towards the comprehensive annual disclosure. Since the document is long (48k chars) and detailed, it is not a simple RPA. It contains the core content of the annual results. If this were a US filer, it would be the 10-K. For a UK company announcing audited results, the closest equivalent covering the full year's performance is the Annual Report (AR) or, if it's the initial press release of those results, the Earnings Release (ER). Given the context of providing the full year's audited results and dividend details, 'AR' (Audit Report / Information) is a possibility, but 'ER' (Earnings Release) is often used for the initial release of annual/quarterly results. Since it covers the full year and mentions 'audited results', it functions as the primary annual financial disclosure. I will classify it as 'AR' (Audit Report / Information) as it contains the audited results summary, which is more specific than a general ER, although it shares characteristics with both ER and 10-K. Re-evaluating the definitions: 10-K is the official yearly report. AR is 'Standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests (excluding full Annual Reports)'. Since this document *is* the summary of the full year's audited results, it is functionally the core of the Annual Report. Given the options, and recognizing this is the primary annual financial disclosure, I will select 'AR' as the best fit among the provided codes that aren't '10-K' (which is reserved for US SEC filings) or 'ER' (which is often quarterly). However, the content is a full-year result announcement. If '10-K' is reserved for SEC filings, 'AR' is the next best fit for a comprehensive annual report summary, or 'ER' if it's the initial press release. Given the depth, I lean towards the comprehensive annual disclosure category, 'AR'. Let's check the dividend announcement: 'Second interim dividend of 62p per share (2020: 52p)' and 'Special dividend of 38p per share (2020: 53p)' are strong indicators of an annual results announcement. I will classify this as 'ER' as it is the initial announcement of the results, even though it covers the full year, aligning with the function of an Earnings Release. FY 2021
2021-10-18 English
Bioventix Plc - Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and details changes in voting rights ('An acquisition or disposal of voting rights') by a shareholder (Danske Bank A/S) in the issuer (BIOVENTIX PLC). This type of mandatory disclosure regarding changes in significant share ownership thresholds is classified as a Major Shareholding Notification.
2021-08-31 English
Bioventix Plc - Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is a 'TR-1: Standard form for notification of major holdings' sent to the issuer and the FCA. It details an acquisition or disposal of voting rights by Danske Bank A/S on behalf of various Danske Invest entities, crossing a notification threshold (4.007884%). This type of mandatory disclosure regarding changes in significant share ownership directly corresponds to the definition of a Major Shareholding Notification.
2021-08-11 English
Bioventix Plc - Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains structured tables detailing changes in voting rights and share ownership percentages for a specific issuer (BIOVENTIX PLC). This format is characteristic of regulatory filings related to insider or major shareholder transactions, specifically concerning the crossing or reaching of notification thresholds. This aligns directly with the definition of 'Major Shareholding Notification' (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2021-07-21 English
Bioventix Plc - Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is a 'TR-1: Standard form for notification of major holdings' submitted to the FCA (Financial Conduct Authority) regarding Bioventix Plc. Section 2 explicitly states the reason for notification is 'An acquisition or disposal of voting rights'. Section 7 details the resulting percentage of voting rights held by Danske Bank A/S and its related entities, crossing a threshold. This type of mandatory disclosure concerning changes in significant share ownership aligns directly with the definition of Major Shareholding Notification (MRQ).
2021-06-08 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.